MYC-mediated resistance to trametinib and HCQ in PDAC is overcome by CDK4/6 and lysosomal inhibition

Pharmacological inhibition of KRAS>RAF>MEK1/2>ERK1/2 signaling has provided no clinical benefit to patients with pancreatic ductal adenocarcinoma (PDAC). Interestingly, combined inhibition of MEK1/2 (with trametinib [T]) plus autophagy (with chloroquine [CQ] or hydroxychloroquine [HCQ]) dem...

Descripción completa

Detalles Bibliográficos
Autores principales: Silvis, Mark R., Silva, Dilru, Rohweder, Riley, Schuman, Sophia, Gudipaty, Swapna, Truong, Amanda, Yap, Jeffrey, Affolter, Kajsa, McMahon, Martin, Kinsey, Conan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Rockefeller University Press 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9930170/
https://www.ncbi.nlm.nih.gov/pubmed/36719686
http://dx.doi.org/10.1084/jem.20221524

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9930170/
https://www.ncbi.nlm.nih.gov/pubmed/36719686
http://dx.doi.org/10.1084/jem.20221524

Ejemplares similares